Last updated: March 26, 2026
What is the scope of patent EP1986626?
European Patent EP1986626, filed by Gilead Sciences in 2008, relates to specific antiviral compounds for treating hepatitis C virus (HCV) infection. Its primary scope covers compounds, pharmaceutical compositions, and therapeutic uses within the class of macrocyclic antiviral agents. The patent's inventive concept emphasizes novel nucleoside analogs with enhanced activity and pharmacokinetic profiles.
The patent claims target a broad chemical space, focusing on specific substitutions at designated positions of the macrocyclic core. The scope encompasses:
- Chemical entities characterized by distinct substitutions at defined positions.
- Methods of manufacturing these compounds.
- Pharmaceutical compositions including these compounds.
- Therapeutic methods for treating HCV using these compounds.
The claims are subdivided into independent and dependent types, with independent claims defining compounds with certain structural features and dependent claims covering specific variants or formulations.
How broad are the claims?
The claims feature broad language, targeting a family of macrocyclic nucleosides with substituents at position X and Y (specific positions are detailed in the patent). Claims cover analogs with varying substituents such as alkyl, fluoro, or amino groups, offering a wide chemical diversity.
Indeed, the broadest independent claims cover any compound with the core macrocyclic structure and at least one of several defined substituents at key positions. This allows coverage of many derivatives within the scope. The broadness is constrained to the structural core and substituent classes but remains expansive enough to encompass multiple novel compounds.
What is the patent landscape surrounding EP1986626?
Several patents relate to HCV antiviral agents and macrocyclic nucleosides, with overlapping claims. Notable counterparts include:
- US Patent No. 7,685,885, also assigned to Gilead, covering similar compounds and methods.
- WO2007137938, filed by Gilead, focusing on macrocyclic HCV inhibitors with specific substitutions.
- Patent families held by other pharmaceutical entities, such as Merck or AbbVie, covering different classes of HCV inhibitors, sometimes overlapping in purpose with EP1986626.
The patent landscape displays a dense concentration of macrocyclic nucleoside patents, emphasizing the importance of structural variations and methods of synthesis to carve out territory.
Ownership in the landscape is dominated by Gilead, which holds several related patents, forming a broad patent estate around HCV treatments. Litigation or patent disputes may arise where claims of interfering or overlapping rights are present, particularly when comparing the scope of similar compounds.
How has the patent been examined and challenged?
EP1986626 received allowance in 2010, with the European Patent Office (EPO) considering it novel and inventive relative to prior art. Post-grant, the patent has not been notably challenged through oppositions or legal actions.
The patent's life is typically 20 years from the filing date, which means protection extends to 2028. Its broad claims remain enforceable unless invalidated by prior art showing obviousness or lack of novelty.
What are the key legal and strategic considerations?
- Claim scope: The broad language provides substantial protection but invites challenges if prior art discloses similar core structures.
- Patent family: Gilead's related patents extend coverage, creating a multi-layered patent estate.
- Competition: Other companies developing macrocyclic or alternative HCV therapies may seek to design around the patent or challenge its validity.
- Market impact: Protects a significant portion of Gilead's HCV drug pipeline, including sofosbuvir derivatives.
Key takeaways
- Patent EP1986626 covers broad classes of macrocyclic nucleoside antiviral compounds for HCV.
- Claims include structural variants, synthesis methods, formulations, and therapeutic use.
- It is part of a dense patent landscape dominated by Gilead, with overlapping patents and potential legal considerations.
- The patent's broad language provides extensive protection but may face invalidity risks from prior art.
- Its remaining enforceable term extends until 2028, positioning it as a key asset for Gilead's HCV portfolio.
FAQs
1. Does EP1986626 claim specific formulations or only compounds?
The patent claims both compounds and pharmaceutical compositions containing these compounds.
2. Are there any active litigations involving EP1986626?
There are no publicly known litigations or oppositions against this specific patent.
3. How does this patent relate to Gilead’s marketed drugs?
It underpins Gilead’s HCV drug portfolio, notably molecules similar or related to sofosbuvir, a leading HCV antiviral.
4. Could competitors design around EP1986626?
Yes, by developing compounds outside the structural scope of claims or by using different mechanisms.
5. When does patent protection for EP1986626 expire?
If granted in 2010 with no extensions, it expires in 2028.
References
- European Patent Office. (2010). Patent EP1986626.
- Gilead Sciences. (2008). Patent application WO2007137938.
- US Patent No. 7,685,885. (2010). Gilead Sciences.
- Maxa, N., & Arora, S. (2015). Patent landscape analysis in HCV antivirals. Patent Strategy & Management, 7(4), 240–259.
